Results 21 to 30 of about 605,792 (294)

Somatostatin analogs: is one better than other? [PDF]

Therapeutic Advances in Medical Oncology, 2017
Rossana Berardi, Stefano Partelli, Stefano Cascinu, Massimo Falconi   +3 more
doaj   +2 more sources

Somatostatin analog therapy effectiveness on the progression of polycystic kidney and liver disease: A systematic review and meta-analysis of randomized clinical trials.

PLoS ONE, 2021
BackgroundUncertainty underlies the effectiveness of somatostatin analogues for slowing the progression of polycystic kidney or liver disease.MethodsEligible studies included randomized controlled trials (RCTs) evaluating somatostatin analog as therapy ...
Tatsuya Suwabe, Francisco J Barrera, Rene Rodriguez-Gutierrez, Yoshifumi Ubara, Marie C Hogan   +4 more
doaj   +1 more source

Study Protocol of the PreFiPS Study: Prevention of Postoperative Pancreatic Fistula by Somatostatin Compared With Octreotide, a Prospective Randomized Controlled Trial

Frontiers in Medicine, 2021
Background: Pancreatic fistula (PF), i. e., a failure of the pancreatic anastomosis or closure of the remnant pancreas after distal pancreatectomy, is one of the most feared complications after pancreatic surgery.
Elisabeth Hain, Alexandre Challine, Stylianos Tzedakis, Alexandru Mare, Alessandro Martinino, David Fuks, Mustapha Adham, Guillaume Piessen, Jean-Marc Regimbeau, Emmanuel Buc, Louise Barbier, Jean-Christophe Vaillant, Florence Jeune, Laurent Sulpice, Fabrice Muscari, Lilian Schwarz, Sophie Deguelte, Antonio Sa Cunha, Stephanie Truant, Bertrand Dousset, Alain Sauvanet, Sébastien Gaujoux   +21 more
doaj   +1 more source

A transplantable phosphorylation probe for direct assessment of G protein-coupled receptor activation. [PDF]

PLoS ONE, 2012
The newly developed multireceptor somatostatin analogs pasireotide (SOM230), octreotide and somatoprim (DG3173) have primarily been characterized according to their binding profiles.
Andrea Kliewer, Anika Mann, Aline Petrich, Florian Pöll, Stefan Schulz   +4 more
doaj   +1 more source

Somatostatin venom analogs evolved by fish-hunting cone snails: From prey capture behavior to identifying drug leads

bioRxiv, 2021
Somatostatin (SS) is a peptide hormone with diverse physiological roles. By investigating a deep-water clade of fish-hunting cone snails, we show that predator-prey evolution has generated a diverse set of SS analogs, each optimized to elicit specific ...
I. B. Ramiro, Walden E. Bjørn-Yoshimoto, J. Imperial, J. Gajewiak, M. Watkins, Dylan Taylor, William Resager, B. Ueberheide, H. Bräuner‐Osborne, F. Whitby, C. Hill, Laurent F Martin, A. Patwardhan, G. Concepcion, B. Olivera, Helena Safavi-Hemami   +15 more
semanticscholar   +1 more source

Comparison between somatostatin analog injections

Revista da Associação Médica Brasileira, 2022
Long-acting depot formulations of somatostatin analogs, i.e., octreotide and lanreotide, are the first-line medical therapies for patients with acromegaly to whom surgery/radiotherapy cannot be performed or who have inadequate response. In this study, we aimed to evaluate the short-term local and systemic adverse reactions developed after the ...
Emre Gezer, Yeliz Demirhan, Alev Selek, Zeynep Cantürk, Berrin Çetinarslan, Mehmet Sözen, Damla Köksalan, Ayfer Peker Karatoprak   +7 more
openaire   +5 more sources

Response and relapse rates after treatment with long-acting somatostatin analogs in multifocal or recurrent type-1 gastric carcinoids: A systematic review and meta-analysis

United European Gastroenterology journal, 2020
Background Type-1 gastric neuroendocrine tumors represent a recurring disease and long-acting somatostatin analogs can inhibit both gastrin release and endocrine cell proliferation. The efficacy and timing of this treatment are still unclear.
R. Rossi, P. Invernizzi, V. Mazzaferro, S. Massironi   +3 more
semanticscholar   +1 more source

The pathophysiological consequences of somatostatin receptor internalization and resistance [PDF]

, 2003
Somatostatin receptors expressed on tumor cells form the rationale for somatostatin analog treatment of patients with somatostatin receptor-positive neuroendocrine tumors.
Hofland, L.J. (Leo), Lamberts, S.W.J. (Steven)   +1 more
core   +3 more sources

Growth Hormone (GH)-Releasing Peptide Stimulation of GH Release from Human Somatotroph Adenoma Cells: Interaction with GH-Releasing Hormone, Thyrotropin- Releasing Hormone, and Octreotide. [PDF]

, 1994
The synthetic hexapeptide GH-releasing peptide (GHRP; His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) specifically stimulates GH secretion in humans in vivo and in animals in vitro and in vivo via a still unknown receptor and mechanism.
Brockmeier, S., Lange, M., Müller, Otto-Albrecht, Renner, U., Schopohl, Jochen, Stalla, G. K., Strasburger, Christian J., Werder, K. von   +7 more
core   +1 more source

DISSOCIATION OF BIOCHEMICAL AND TUMOR-SUPRESSIVE EFFECTS OF SOMATOSTATIN ANALOGS

Alʹmanah Kliničeskoj Mediciny, 2016
Normalization of the growth hormone and IGF-1 levels during somatostatin analogs treatment usually is a predictor of somatotropinoma volume reduction.
A. V. Dreval’, I. A. Ilovayskaya, Yu. G. Pokramovich, G. A. Stashuk, R. S. Tishenina   +4 more
doaj   +1 more source